ofirnoflast   Click here for help

GtoPdb Ligand ID: 13227

Synonyms: example 10 [WO2021242505]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for ofirnoflast was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serine/ threonine-protein kinase NEK7 inhibitor with anti-inflammatory potential. It is one of the examples claimed in Halia Therapeutics' patent WO2021242505A1 [1]. NEK7 inhibitors are being explored for anti-inflammatory activity that is mediated via inhibition of NLRP3 inflammasome activation thereby leading to reduced production of the pro-inflammatory cytokines IL-1β and IL-18. Halia Therapeutics have several NEK7 inhibitors in their development pipeline, the most advanced of which is HT-6184 (phase 2 for inflammatory pain). However, without further information or disclosures we cannot definitively identify the code name for ofirnoflast (March 2024).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 116.7
Molecular weight 501.44
XLogP 2.17
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=CC(=C(C=C1C2=CN(C3CC3)C4=C2C(=NC=N4)N)F)NC(=O)NC5=NOC(=C5)C6(CC6)C(F)(F)F
Isomeric SMILES NC=1C2=C(N=CN1)N(C=C2C3=CC(=C(C=C3)NC(=O)NC4=NOC(=C4)C5(CC5)C(F)(F)F)F)C6CC6
InChI InChI=1S/C23H19F4N7O2/c24-14-7-11(13-9-34(12-2-3-12)20-18(13)19(28)29-10-30-20)1-4-15(14)31-21(35)32-17-8-16(36-33-17)22(5-6-22)23(25,26)27/h1,4,7-10,12H,2-3,5-6H2,(H2,28,29,30)(H2,31,32,33,35)
InChI Key MJUUWYZZPRAKCW-UHFFFAOYSA-N
Immunopharmacology Comments
Small molecule inhibitors that directly target NEK7 to downregulate the inflammatory response modulated by the NLRP3 inflammasome (to abolish production of the pro-inflammatory cytokines IL-1β and IL-18) offer potential to treat inflammation-mediated pathology, either as therapeutics or prophylactics.